 Connection
Paul Toren to Aryl Hydrocarbon Hydroxylases
This is a "connection" page, showing publications Paul Toren has written about Aryl Hydrocarbon Hydroxylases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.390 |
|
|
|
-
Kyler KE, Gaedigk A, Abdel-Rahman S, Staggs VS, Pearce RE, Toren P, Leeder JS, Shakhnovich V. Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children. Clin Transl Sci. 2024 04; 17(4):e13782.
Score: 0.230
-
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011 Nov; 39(11):2020-33.
Score: 0.096
-
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006 Jan; 34(1):191-7.
Score: 0.064
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|